NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $27.35 +0.02 (+0.07%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$27.40 +0.05 (+0.18%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARQT alerts:Sign Up Key Stats Today's Range$26.78▼$27.6950-Day Range$19.50▼$28.7852-Week Range$13.69▼$31.77Volume819,320 shsAverage Volume1.43 million shsMarket Capitalization$3.42 billionP/E RatioN/ADividend YieldN/APrice Target$34.00Consensus RatingModerate Buy Company Overview Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options. In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies. Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.AI Generated. May Contain Errors. Read More Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreARQT MarketRank™: Arcutis Biotherapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 242nd out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialArcutis Biotherapeutics has a consensus price target of $34.00, representing about 24.3% upside from its current price of $27.35.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth500.00% Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow by 500.00% in the coming year, from $0.16 to $0.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -911.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -911.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 17.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.97% of the float of Arcutis Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 9.34.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.99 News SentimentArcutis Biotherapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcutis Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat Follows2 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $730,086.00 in company stock.Percentage Held by Insiders9.40% of the stock of Arcutis Biotherapeutics is held by insiders.Percentage Held by InstitutionsArcutis Biotherapeutics has minimal institutional ownership at this time.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARQT Stock News HeadlinesAnalysts Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target at $34.00July 25 at 3:36 AM | americanbankingnews.comArcutis: Intense Competition, Costs, Slow Growth Merit Downgrade To HoldJuly 23 at 9:56 AM | seekingalpha.comUniversal Basic Income ALREADY existsRobert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal basic income. His Patriot Income Plan - funded by 14 partnerships controlling America's critical oil and gas infrastructure - already pays 10% a year with 42 payouts annually. Some investors are already collecting $4,800 a month. One has built income up to $25,000 a month. These partnerships have averaged 20% annual gains since 2020, with no U.S. tax dollars involved. The next payout drops in days.July 26 at 1:00 AM | Freedom Financial (Ad)Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT)July 19, 2026 | theglobeandmail.comArcutis Expands Board of Directors with Appointment of Chris PeetzJuly 16, 2026 | globenewswire.comArcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026July 15, 2026 | globenewswire.comArcutis Biotherapeutics (ARQT) Receives a Buy from JefferiesJuly 11, 2026 | theglobeandmail.comBiotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin TreatmentJuly 9, 2026 | investors.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $29.04 at the beginning of the year. Since then, ARQT shares have decreased by 5.8% and is now trading at $27.35. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its earnings results on Wednesday, May, 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.07. The business had revenue of $105.40 million for the quarter, compared to analysts' expectations of $103.68 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative trailing twelve-month return on equity of 1.41%. Read the conference call transcript. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $150 million in an IPO on Friday, January 31st 2020. The company issued 9,375,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' top institutional shareholders include Handelsbanken Fonder AB (0.04%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Todd Watanabe, Larry Todd Edwards, David Joseph Topper, Masaru Matsuda, Patrick Burnett, Latha Vairavan, Howard G Welgus, Sue-Jean Lin, Patrick J Heron, Neha Krishnamohan, Halley E Gilbert and Terrie Curran. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA). Company Calendar Last Earnings5/06/2026Today7/26/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (23m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ARQT's financial health is in the Green zone, according to TradeSmith. ARQT has been in this zone for over 23 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Price Target for Arcutis Biotherapeutics$34.00 High Price Target$36.00 Low Price Target$29.00 Potential Upside/Downside+24.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E Ratio170.94 P/E GrowthN/ANet Income-$16.14 million Net Margins-0.57% Pretax Margin-0.33% Return on Equity-1.41% Return on Assets-0.59% Debt Debt-to-Equity Ratio0.54 Current Ratio2.68 Quick Ratio2.46 Sales & Book Value Annual Sales$376.07 million Price / Sales9.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book17.65Miscellaneous Outstanding Shares125,080,000Free Float113,325,000Market Cap$3.42 billion OptionableOptionable Beta1.48 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ARQT) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredThe pact that ran the world and dollar just expiredIn 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...Golden Portfolio | SponsoredThe invention Elon called the greatest in historyJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
